ESR1 and breast carcinoma: To model in parallel elacestrant and fulvestrant treatment of a PDX breast tumor model, we made use of fulvestrant naive MAXF-713 cells, derived from a 60-year-old patient with untreated ER+/PR+/Her2- breast cancer [22].